Developing a PET Volumetric Staging System for NSCLC: a Complement to TNM Staging

描述(申请人提供)：目前，非小细胞肺癌(NSCLC)的治疗和预后评估主要取决于UICC/AJCC TNM(肿瘤、淋巴结和转移)分期系统。现代18F-FDGPET/CT在非小细胞肺癌患者的诊断、分期和再分期中发挥着重要作用，并提供三维(3D)代谢和体积图像数据。然而，基于肿瘤手术可切除性的TNM分期系统没有结合肿瘤体积数据的机制。最近，我们和其他小组发现，在手术和非手术治疗的NSCLC患者中，在调整了TNM分期、肿瘤SUV和其他临床预后指标(包括年龄、性别、表现状态、治疗类型和肿瘤组织学)后，基线代谢性肿瘤负荷(MTB)是一个预后指标，并且优于肿瘤标准化摄取值(SUV)测量。在PET/CT上测量结核分枝杆菌是实用和可重复性的，观察者间的变异性很小--平均一致性相关系数大于0.94。参考临床PET/CT和CT报告，每例手术患者的全身MTB测量时间约为3.6分钟。然而，尽管有这些有希望的发现，目前还没有有效的方法将MTB测量纳入非小细胞肺癌患者的TNM分期系统或临床管理。为此，我们建议开发一种基于PET/CT的体积预测(PVP)分期系统，将MTB测量和当前的TNM分期系统结合起来，以更好地预测非小细胞肺癌的预后。我们提出了两个具体的目标：(1)通过开发两个不同的相互竞争的数学模型，开发一个新的基于PET/CT的非小细胞肺癌PVP分期系统；(2)用来自不同机构的新数据集来验证新的PVP分期系统。我们的长期目标是协同目前的TNM分期系统和容量MTB测量的预后价值。预计公共卫生意义将体现在以下三个方面：1)通过提供更准确的肿瘤分期和风险分层，改善非小细胞肺癌患者的治疗选择；2)通过提供更准确的预后评估，帮助临床医生和患者；以及3)帮助在临床试验中更好地确定患者选择标准。该方案的创新包括：1)提出了基于PET/CT的新的PVP分期系统，以更准确地预测非小细胞肺癌的预后；2)利用PET/CT的三维体积和代谢数据进行非小细胞肺癌分期，具有创新性；以及3)通过PVP分期系统使非小细胞肺癌分期更加定量。

DESCRIPTION (provided by applicant): Currently, treatment and prognostic assessment for non-small cell lung cancer (NSCLC) depend primarily on the UICC/AJCC TNM (tumor, node, and metastasis) staging system. Modern 18F-FDG PET/CT plays an important role in the diagnosis, staging, and restaging of patients with NSCLC and provides three-dimensional (3D) metabolic and volumetric image data. However, the TNM staging system, based on surgical resectability of the tumor, has no mechanism to incorporate tumor volumetric data. Recently, we and other groups have found that baseline metabolic tumor burden (MTB) is a prognostic indicator of survival and is better than tumor standardized uptake value (SUV) measurement, in both surgically and non-surgically treated NSCLC patients, after adjusting for TNM stage, tumor SUV, and other clinical prognostic indicators including age, gender, performance status, treatment type, and tumor histology. Measurement of MTB on PET/CT is practical and reproducible with low inter-observer variability-with a mean concordance correlation coefficient greater than 0.94. It takes about 3.6 minutes to measure whole-body MTBs in each surgically treated patient with reference of clinical PET/CT and CT reports based our retrospective study. However, despite these promising findings, there is currently no effective method to incorporate MTB measurement into the TNM staging system or clinical management of NSCLC patients. To that end, we propose to develop a PET/CT-based volumetric prognostic (PVP) staging system that combines MTB measurements and the current TNM staging system for better prognostication in NSCLC. We propose two specific aims: (1) to develop a new PET/CT-based PVP staging system for NSCLC by developing two different competing mathematical models, and (2) to validate the novel PVP staging system with new datasets of patients from different institutions. Our long-term objective is to synergize the prognostic value of the current TNM staging system and volumetric MTB measurement. The public health significance is expected in the following three areas: 1) to improve patient treatment selection in NSCLC by providing more accurate tumor staging and risk- stratification, 2) to assist clinicians and patients by providing more accurate prognostic assessment, and 3) to help better define patient selection criteria in clinical trials. The innovations of the proposal include the following: 1) the proposed new PET/CT-based PVP staging system for more accurate prognostication in NSCLC is innovative; 2) making use of 3D volumetric and metabolic data from PET/CT for NSCLC staging is innovative; and 3) making NSCLC staging more quantitative with the PVP staging system is innovative.